-+ 0.00%
-+ 0.00%
-+ 0.00%

BioMarin submits FDA sNDA for VOXZOGO in hypochondroplasia

PUBT·10/09/2026 13:05:32
Listen to the news
BioMarin submits FDA sNDA for VOXZOGO in hypochondroplasia
  • BioMarin filed an sNDA with the FDA seeking to expand VOXZOGO to treat hypochondroplasia.
  • Regulatory submissions to the EMA, other health authorities remain on track.
  • If cleared, VOXZOGO would become the first targeted hypochondroplasia therapy, positioning a potential 2027 launch.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioMarin Pharmaceutical Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610090905PR_NEWS_USPR_____SF66672) on October 09, 2026, and is solely responsible for the information contained therein.